Novartis Ag (NVS) EPS (Weighted Average and Diluted) (2009 - 2025)
Novartis Ag recorded quarterly EPS (Weighted Average and Diluted) of $1167.8 in Q2 2025, down 1.65% quarter-over-quarter from $1187.4 in Q4 2024, and down 12.14% year-over-year from $1329.1 in Q2 2024.
Novartis Ag's EPS (Weighted Average and Diluted) history runs 17 years deep, the most recent figure standing at $1167.8 for Q2 2025.
- In Q2 2025, EPS (Weighted Average and Diluted) fell 12.14% year-over-year to $1167.8; the TTM figure through Mar 2026 stood at $2746.1 (down 53.77% YoY), while the FY2025 annual figure was $1955.8, down 3.86% from the prior year.
- EPS (Weighted Average and Diluted) came in at $1167.8 for Q2 2025 at Novartis Ag, down from $1187.4 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2891.5 in Q2 2022 to a low of $42.2 in Q2 2023.
- A 5-year average of $780.79 and a median of $560.3 in 2021 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) plunged 98.54% in 2023 and jumped 3049.31% in 2024, its largest moves.
- Novartis Ag's EPS (Weighted Average and Diluted) stood at $560.3 in 2021, then sank by 90.2% to $54.91 in 2022, then declined by 15.6% to $46.34 in 2023, then surged by 2462.27% to $1187.4 in 2024, then retreated by 1.65% to $1167.8 in 2025.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered $1167.8, $1187.4, and $1329.1 for Q2 2025, Q4 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 8.26 |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 2.14 |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 0.39 |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -1.72 |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 3.34 |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 1.61 |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 0.47 |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 1.31 |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1,167.78 |
| Dec 31, 2024 | 1,187.39 |
| Jun 30, 2024 | 1,329.07 |
| Dec 31, 2023 | 46.34 |
| Sep 30, 2023 | 88.34 |
| Jun 30, 2023 | 42.20 |
| Mar 31, 2023 | 142.57 |
| Dec 31, 2022 | 54.91 |
| Sep 30, 2022 | 114.49 |
| Jun 30, 2022 | 2,891.48 |
| Mar 31, 2022 | 601.01 |
| Dec 31, 2021 | 560.30 |
| Sep 30, 2021 | 188.27 |
| Jun 30, 2021 | 2,732.88 |
| Mar 31, 2021 | 564.84 |
| Dec 31, 2020 | 1,394.60 |
| Sep 30, 2020 | 232.31 |
| Jun 30, 2020 | 3,181.82 |
| Mar 31, 2020 | 204.21 |
| Mar 31, 2019 | -132.89 |
| Dec 31, 2018 | -4.83 |
| Sep 30, 2018 | -52.98 |
| Jun 30, 2018 | 12.16 |
| Mar 31, 2018 | 69.05 |
| Dec 31, 2017 | 157.85 |
| Sep 30, 2017 | 243.57 |
| Jun 30, 2017 | 2,789.16 |
| Mar 31, 2017 | 747.14 |
| Dec 31, 2016 | 3.21 |
| Sep 30, 2016 | 220.00 |
| Jun 30, 2016 | 746.67 |
| Mar 31, 2016 | 220.24 |
| Dec 31, 2015 | 0.69 |
| Sep 30, 2015 | 34.02 |
| Jun 30, 2015 | 0.00 |
| Mar 31, 2015 | 0.00 |
| Dec 31, 2014 | 0.00 |
| Sep 30, 2014 | 0.00 |
| Jun 30, 2014 | 0.00 |
| Mar 31, 2014 | 0.00 |
| Sep 30, 2013 | 0.00 |
| Jun 30, 2013 | 0.00 |
| Sep 30, 2012 | 0.00 |
| Jun 30, 2012 | 0.00 |
| Mar 31, 2012 | 0.00 |
| Dec 31, 2011 | 0.00 |
| Sep 30, 2011 | 0.00 |
| Jun 30, 2011 | 0.00 |
| Mar 31, 2011 | 0.00 |
| Dec 31, 2010 | 0.00 |
| Sep 30, 2010 | 0.00 |
| Jun 30, 2010 | 0.00 |
| Mar 31, 2010 | 0.00 |
| Dec 31, 2009 | 0.00 |
| Sep 30, 2009 | 0.00 |
| Jun 30, 2009 | 0.00 |
| Mar 31, 2009 | 0.00 |